TY - JOUR
AU - Mark Powell
AU - Eric Ebel
AU - Wayne Schlosser
AU - Mark Walderhaug
AU - Janell Kause
AB - Escherichia coli O157:H7 is an emerging food and waterborne pathogen in the U.S. and internationally. The objective of this work was to develop a dose-response model for illness by this organism that bounds the uncertainty in the dose-response relationship. No human clinical trial data are available for E. coli O157:H7, but such data are available for two surrogate pathogens: enteropathogenic E. coli (EPEC) and Shigella dysenteriae. E. coli O157:H7 outbreak data provide an initial estimate of the most likely value of the dose-response relationship within the bounds of an envelope de®ned by beta-Poisson dose-response models ®t to the EPEC and S. dysenteriae data. The most likely value of the median effective dose for E. coli O157:H7 is estimated to be approximately 190 000 colony forming units (cfu). At a dose level of 100 cfu, the median response predicted by the model is six percent.
LA - eng
N2 - Escherichia coli O157:H7 is an emerging food and waterborne pathogen in the U.S. and internationally. The objective of this work was to develop a dose-response model for illness by this organism that bounds the uncertainty in the dose-response relationship. No human clinical trial data are available for E. coli O157:H7, but such data are available for two surrogate pathogens: enteropathogenic E. coli (EPEC) and Shigella dysenteriae. E. coli O157:H7 outbreak data provide an initial estimate of the most likely value of the dose-response relationship within the bounds of an envelope de®ned by beta-Poisson dose-response models ®t to the EPEC and S. dysenteriae data. The most likely value of the median effective dose for E. coli O157:H7 is estimated to be approximately 190 000 colony forming units (cfu). At a dose level of 100 cfu, the median response predicted by the model is six percent.
EP - 24
TI - Dose-{Response} {Envelope} for {Escherichia} coli
ER -